In vitro modeling of COPD inflammation and limitation of p38 inhibitor — SB203580
Aihong Meng,1 Xiaopeng Zhang,2 Siyu Wu,1 Mingxia Wu,1 Jing Li,1 Xixin Yan,1 Kamilla Kopec-Harding,3 Jiakai Wu41Respiratory Division, The Second Hospital of Hebei Medical University, 2Department of Thoracic Surgery, Hebei Province General Hospital, Shijiazhuang, Hebei, Peoples’ Republic of...
Main Authors: | Meng AH, Zhang XP, Wu SY, Wu MX, Li J, Yan XX, Kopec-Harding K, Wu JK |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-04-01
|
Series: | International Journal of COPD |
Subjects: | |
Online Access: | https://www.dovepress.com/in-vitro-modeling-of-copd-inflammation-and-limitation-of-p38-inhibitor-peer-reviewed-article-COPD |
Similar Items
-
The p38 MAPK Inhibitor SB203580 Abrogates Tumor Necrosis Factor-Induced Proliferative Expansion of Mouse CD4+Foxp3+ Regulatory T Cells
by: Tianzhen He, et al.
Published: (2018-07-01) -
Role of p38 Mitogen-Activated Protein Kinase in Asthma and COPD: Pathogenic Aspects and Potential Targeted Therapies
by: Pelaia C, et al.
Published: (2021-03-01) -
P38 MAPK Pharmacological Inhibitor SB203580 Alleviates Total Parenteral Nutrition-Induced Loss of Intestinal Barrier Function but Promotes Hepatocyte Lipoapoptosis
by: Yong-Tao Xiao, et al.
Published: (2017-02-01) -
Pharmacological Inhibition of p38 MAPK by SB203580 Increases Resistance to Carboplatin in A2780cp Cells and Promotes Growth in Primary Ovarian Cancer Cells
by: Xiaolu Han, et al.
Published: (2018-07-01) -
Synthesis and p38 Inhibitory Activity of Some Novel Substituted N,N′-Diarylurea Derivatives
by: Dianxi Zhu, et al.
Published: (2016-05-01)